Genetic landscape of homologous recombination repair genes in early‐onset/familial prostate cancer patients
Genes, Chromosomes and Cancer · 2023-12 · 62 (12) · 710-720
DOI: 10.1002/gcc.23190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, online erschienen am 12.07.2023. Verfasst von Paula Paulo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Genetics Group, IPO Porto Research Center (CI-IPOP) /RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Carcinoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Fundação para a Ciência e a Tecnologia.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Prostate cancer (PrCa) is one of the three most frequent and deadliest cancers worldwide. The discovery of PARP inhibitors for the treatment of tumors with deleterious variants in homologous recombination repair (HRR) genes has placed PrCa on the roadmap of precision medicine. However, the overall contribution of HRR genes to the 10%–20% of carcinomas arising in men with early‐onset/familial PrCa has not been fully clarified. We used targeted next‐generation sequencing (T‐NGS) covering eight HRR genes ( ATM , BRCA1 , BRCA2 , BRIP1 , CHEK2 , NBN , PALB2 , and RAD51C ) and an analysis pipeline querying both small and large genomic variations to clarify their global and relative contribution to hereditary PrCa predisposition in a series of 462 early‐onset/familial PrCa cases. Deleterious variants were found in 3.9% of the patients, with CHEK2 and ATM being the most frequently mutated genes (38.9% and 22.2% of the carriers, respectively), followed by PALB2 and NBN (11.1% of the carriers, each), and finally by BRCA2 , RAD51C , and BRIP1 (5.6% of the carriers, each). Using the same NGS data, exonic rearrangements were found in two patients, one pathogenic in BRCA2 and one of unknown significance in BRCA1 . These results contribute to clarify the genetic heterogeneity that underlies PrCa predisposition in the early‐onset and familial disease, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Genetics Group, IPO Porto Research Center (CI-IPOP) /RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) /Porto Comprehensive Cancer Center, Porto, Portugal.
- Department of Laboratory Genetics, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center, Porto, Portugal.
- Medical Genetics Unit, Hospital Pediátrico de Coimbra, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
- School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
ORCID-Profile: Paula Paulo, Marta Cardoso, Andreia Brandão, Manuel R Teixeira
Förderung
- Fundação para a Ciência e a Tecnologia
Zitieren
APA
Paulo, P., Cardoso, M., Brandão, A., Pinto, P., Falconi, A., Pinheiro, M., Cerveira, N., Silva, R., Santos, C., Pinto, C., Peixoto, A., Maia, S., & Teixeira, M. R. (2023). Genetic landscape of homologous recombination repair genes in early‐onset/familial prostate cancer patients. Genes, Chromosomes and Cancer, 62(12), 710-720. https://doi.org/10.1002/gcc.23190
Vancouver
Paulo P, Cardoso M, Brandão A, Pinto P, Falconi A, Pinheiro M, et al. Genetic landscape of homologous recombination repair genes in early‐onset/familial prostate cancer patients. Genes, Chromosomes and Cancer. 2023;62(12):710-720. doi:10.1002/gcc.23190
BibTeX
@article{Paulo2023,
author = {Paulo, Paula and Cardoso, Marta and Brandão, Andreia and Pinto, Pedro and Falconi, Ariane and Pinheiro, Manuela and Cerveira, Nuno and Silva, Rui and Santos, Catarina and Pinto, Carla and Peixoto, Ana and Maia, Sofia and Teixeira, Manuel R},
title = {Genetic landscape of homologous recombination repair genes in early‐onset/familial prostate cancer patients},
journal = {Genes, Chromosomes and Cancer},
year = {2023},
volume = {62},
number = {12},
pages = {710--720},
doi = {10.1002/gcc.23190}
}
EUVIMED